Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fukiko Furukawa is active.

Publication


Featured researches published by Fukiko Furukawa.


Oncogene | 2004

TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions

Shigeo Mori; Koichi Matsuzaki; Katsunori Yoshida; Fukiko Furukawa; Yoshiya Tahashi; Hideo Yamagata; Go Sekimoto; Toshihito Seki; Hirofumi Matsui; Mikio Nishizawa; Jun-ichi Fujisawa; Kazuichi Okazaki

Although hepatocyte growth factor (HGF) can act synergistically or antagonistically with transforming growth factor-β (TGF-β) signaling, molecular mechanism of their crosstalk remains unknown. Using antibodies which selectively distinguished receptor-regulated Smads (R-Smads) phosphorylated at linker regions from those at C-terminal regions, we herein showed that either HGF or TGF-β treatment of normal stomach-origin cells activated the JNK pathway, thereafter inducing endogenous R-Smads phosphorylation at linker regions. However, the phosphorylation at their C-terminal regions was not induced by HGF treatment. The activated JNK could directly phosphorylate R-Smads in vitro at the same sites that were phosphorylated in response to TGF-β or HGF in vivo. Thus, the linker regions of R-Smads were the common phosphorylation sites for HGF and TGF-β signaling pathways. The phosphorylation induced by simultaneous treatment with HGF and TGF-β allowed R-Smads to associate with Smad4 and to translocate into the nucleus. JNK pathway involved HGF and TGF-β-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-β signals. Moreover, a combined treatment with HGF and TGF-β led to a potent increase in plasminogen activator inhibitor type 1 transcriptional activity through Smad3 phosphorylation at the linker region. In contrast, HGF treatment reduced TGF-β-dependent activation of p15INK4B promoter, in which Smad3 phosphorylation at the C-terminal region was involved. In conclusion, HGF and TGF-β transmit the signals through JNK-mediated R-Smads phosphorylation at linker regions.


American Journal of Pathology | 2005

Transforming Growth Factor-β and Platelet-Derived Growth Factor Signal via c-Jun N-Terminal Kinase-Dependent Smad2/3 Phosphorylation in Rat Hepatic Stellate Cells after Acute Liver Injury

Katsunori Yoshida; Koichi Matsuzaki; Shigeo Mori; Yoshiya Tahashi; Hideo Yamagata; Fukiko Furukawa; Toshihito Seki; Mikio Nishizawa; Jun-ichi Fujisawa; Kazuichi Okazaki

After liver injury, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) regulate the activation of hepatic stellate cells (HSCs) and tissue remodeling. Mechanisms of PDGF signaling in the TGF-β-triggered cascade are not completely understood. TGF-β signaling involves phosphorylation of Smad2 and Smad3 at linker and C-terminal regions. Using antibodies to distinguish Smad2/3 phosphorylated at linker regions from those phosphorylated at C-terminal regions, we investigated Smad2/3-mediated signaling in rat liver injured by CCl4 administration and in cultured HSCs. In acute liver injury, Smad2/3 were transiently phosphorylated at both regions. Although linker-phosphorylated Smad2 remained in the cytoplasm of α-smooth muscle actin-immunoreactive mesenchymal cells adjacent to necrotic hepatocytes in centrilobular areas, linker-phosphorylated Smad3 accumulated in the nuclei. c-Jun N-terminal kinase (JNK) in the activated HSCs directly phosphorylated Smad2/3 at linker regions. Co-treatment of primary cultured HSCs with TGF-β and PDGF activated the JNK pathway, subsequently inducing endogenous linker phosphorylation of Smad2/3. The JNK pathway may be involved in migration of resident HSCs within the space of Disse to the sites of tissue damage because the JNK inhibitor SP600125 inhibited HSC migration induced by TGF-β and PDGF signals. Moreover, treatment of HSCs with both TGF-β and PDGF increased transcriptional activity of plasminogen activator inhibitor-1 through linker phosphorylation of Smad3. In conclusion, TGF-β and PDGF activate HSCs by transmitting their signals through JNK-mediated Smad2/3 phosphorylation at linker regions, both in vivo and in vitro.


Oncogene | 2003

Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.

Yasushi Sugano; Koichi Matsuzaki; Yoshiya Tahashi; Fukiko Furukawa; Shigeo Mori; Hideo Yamagata; Katsunori Yoshida; Masanori Matsushita; Mikio Nishizawa; Jun-ichi Fujisawa; Kyoichi Inoue

Resistance to growth inhibitory effects of transforming growth factor (TGF)-β is a frequent consequence of malignant transformation. On the other hand, serum concentrations of TGF-β, plasminogen activator inhibitor type 1 (PAI-1), and vascular endothelial growth factor (VEGF) are elevated as tumor progresses. The molecular mechanism of autocrine TGF-β signaling and its effects on PAI-1 and VEGF production in human hepatocellular carcinoma (HCC) is unknown. TGF-β signaling involves TGF-β type I receptor-mediated phosphorylation of serine residues within the conserved SSXS motif at the C-terminus of Smad2 and Smad3. To investigate the involvement of autocrine TGF-β signal in cell growth, PAI-1 and VEGF production of HCC, we made stable transfectants of human HCC line (HuH-7 cells) to express a mutant Smad2(3S-A), in which serine residues of SSXS motif were changed to alanine. The transfectants demonstrated an impaired Smad2 signaling. Along with the resistance to growth inhibition by TGF-β, forced expression of Smad2(3S-A) induced endogenous TGF-β secretion. Moreover, this increased TGF-β enhanced ligand-dependent signaling through the activated Smad3 and Smad4 complex, and transcriptional activities of PAI-1 and VEGF genes. In conclusion, distortion of autocrine TGF-β signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.


Hepatology | 2003

p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts.

Fukiko Furukawa; Koichi Matsuzaki; Shigeo Mori; Yoshiya Tahashi; Katsunori Yoshida; Yasushi Sugano; Hideo Yamagata; Masanori Matsushita; Toshihito Seki; Yutaka Inagaki; Mikio Nishizawa; Jun-ichi Fujisawa; Kyoichi Inoue


Hepatology | 2002

Differential regulation of TGF‐β signal in hepatic stellate cells between acute and chronic rat liver injury

Yoshiya Tahashi; Koichi Matsuzaki; Masataka Date; Katsunori Yoshida; Fukiko Furukawa; Yasushi Sugano; Masanori Matsushita; Yasuo Himeno; Yutaka Inagaki; Kyoichi Inoue


Cancer Research | 2005

Acceleration of Smad2 and Smad3 Phosphorylation via c-Jun NH2-Terminal Kinase during Human Colorectal Carcinogenesis

Hideo Yamagata; Koichi Matsuzaki; Shigeo Mori; Katsunori Yoshida; Yoshiya Tahashi; Fukiko Furukawa; Go Sekimoto; Toshihiko Watanabe; Yoshiko Uemura; Noriko Sakaida; Kazuhiko Yoshioka; Yasuo Kamiyama; Toshihito Seki; Kazuichi Okazaki


Cancer Research | 2000

Autocrine Stimulatory Mechanism by Transforming Growth Factor β in Human Hepatocellular Carcinoma

Koichi Matsuzaki; Masataka Date; Fukiko Furukawa; Yoshiya Tahashi; Masanori Matsushita; Kazushige Sakitani; Noriyo Yamashiki; Toshihito Seki; Hidetsugu Saito; Mikio Nishizawa; Jun-ichi Fujisawa; Kyoichi Inoue


Hepatology | 2000

Regulatory mechanisms for transforming growth factor β as an autocrine inhibitor in human hepatocellular carcinoma: Implications for roles of Smads in its growth

Koichi Matsuzaki; Masataka Date; Fukiko Furukawa; Yoshiya Tahashi; Masanori Matsushita; Yasushi Sugano; Noriyo Yamashiki; Taichi Nakagawa; Toshihito Seki; Mikio Nishizawa; Jun-ichi Fujisawa; Kyoichi Inoue


Archive | 2004

Antibodies specific for phosphorylation sites and screening methods using the same antibodies

Koichi Matsuzaki; Toshihito Seki; Masanori Matsushita; Yoshiya Tahashi; Fukiko Furukawa; Yasushi Sugano; Shigeo Mori; Hideo Yamagata; Katsunori Yoshida; Mikio Nishizawa; Jun-ichi Fujisawa; Kyoichi Inoue


Archive | 2003

ANTIBODY SPECIFIC TO PHOSPHORYLATION SITE AND SCREENING METHOD USING THE SAME

Jun-ichi Fujisawa; Fukiko Furukawa; Kyoichi Inoue; Masataka Matsushita; Koichi Matsuzaki; Shigeo Mori; Mikio Nishizawa; Hisakimi Seki; Yasushi Sugano; Kenya Tahashi; Hideo Yamagata; Masaki Yoshida; 恭一 井上; 富紀子 古川; 勝紀 吉田; 英生 山縣; 匡孝 松下; 恒一 松崎; 茂生 森; 賢也 田橋; 康 菅野; 順一 藤澤; 幹雄 西澤; 壽仁 關

Collaboration


Dive into the Fukiko Furukawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yoshiya Tahashi

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshihito Seki

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Hideo Yamagata

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kyoichi Inoue

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge